IRIS
RISITANO, ANTONIO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.852
EU - Europa 786
AS - Asia 484
AF - Africa 34
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.165
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.750
CN - Cina 343
IT - Italia 318
NL - Olanda 108
FI - Finlandia 104
CA - Canada 100
IE - Irlanda 88
VN - Vietnam 84
UA - Ucraina 34
CI - Costa d'Avorio 33
DE - Germania 31
SE - Svezia 27
FR - Francia 26
GB - Regno Unito 25
IN - India 23
JP - Giappone 9
PK - Pakistan 7
SG - Singapore 6
PS - Palestinian Territory 4
CH - Svizzera 3
EU - Europa 3
RO - Romania 3
RU - Federazione Russa 3
BE - Belgio 2
BR - Brasile 2
ES - Italia 2
GR - Grecia 2
HK - Hong Kong 2
ID - Indonesia 2
MX - Messico 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AT - Austria 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CL - Cile 1
EG - Egitto 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
KR - Corea 1
LU - Lussemburgo 1
ME - Montenegro 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
SI - Slovenia 1
Totale 3.165
Salva come PNG Salva come JPEG
Città #
Chandler 346
Millbury 171
Princeton 133
Nanjing 124
Boston 122
Des Moines 116
Amsterdam 103
Ottawa 94
Dong Ket 84
Naples 71
Napoli 70
Ashburn 62
Beijing 55
Lawrence 46
Wilmington 41
Jacksonville 36
Shenyang 36
Nanchang 29
Hebei 26
Tianjin 24
Jiaxing 18
Ann Arbor 15
Redwood City 15
Woodbridge 13
Changsha 11
Milan 10
Norwalk 8
Latronico 7
Mountain View 7
Seattle 7
Rome 6
Dalmine 5
Los Angeles 5
New York 5
Tokyo 5
Crispano 4
Frankfurt am Main 4
Glasgow 4
Guangzhou 4
Helsinki 4
Hyderabad 4
Kronberg 4
Pune 4
Stockholm 4
Torre del Greco 4
White Plains 4
Basel 3
Boardman 3
Engelskirchen 3
Fairfield 3
Falls Church 3
Fremont 3
Hamilton 3
Indiana 3
Kunming 3
Montreal 3
Nocera Inferiore 3
Oleggio 3
San Mateo 3
Singapore 3
Tampa 3
Taranto 3
Utrecht 3
Bengaluru 2
Bergamo 2
Bologna 2
Bratislava 2
Canegrate 2
Catania 2
Cesano Boscone 2
Chennai 2
Dublin 2
Edinburgh 2
Frattamaggiore 2
Graulhet 2
Gurgaon 2
Lappeenranta 2
London 2
Madrid 2
Manchester 2
Montegiorgio 2
Nagareyama 2
New Delhi 2
Padova 2
Palermo 2
Pozzuoli 2
Redmond 2
Saint Petersburg 2
Shanghai 2
Sterling 2
Thessaloniki 2
Tours 2
Tulkarm 2
Valencia 2
Verona 2
Amorosi 1
Atlanta 1
Augusta 1
Bahawalpur 1
Baku 1
Totale 2.090
Salva come PNG Salva come JPEG
Nome #
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial 77
Narrative Based Medicine as a tool for needs assessment of patients undergoing hematopoietic stem cell transplantation 55
Eltrombopag for post-transplant cytopenias due to poor graft function 51
Paroxysmal Nocturnal Hemoglobinuria: significant association with specific HLA-A, B, C and DR alleles in Italian patients 46
(Auto-)immune signature in aplastic anemia 44
Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. 42
ALEMTUZUMAB FOR APLASTIC ANEMIA AND RELATED IMMUNE-MEDIATED BONE MARROW FAILURES: LONG-TERM FOLLOW UP OF A PILOT STUDY 41
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 40
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 40
Long-lasting bone damage detected by dual-energy x-ray absorptiometry,phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation 39
Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab). 38
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future 38
Killer Immunoglobulin-like Receptors (KIR) and their HLA-ligands in Italian Paroxysmal Nocturnal Haemoglobinuria (PNH) patients 37
Antilymphocyte globulin for prevention of chronic graft-versus-host disease 37
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey 37
LONG-TERM FOLLOW UP OF ALENTUZUMAB-BASED IMMUNOSUPPRESSION FOR THE TREATMENT OF IMMUNE-MEDIATED BONE MARROW FAILURE SYNDROMES 36
PEGYLATED-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE 36
Acute immune toxicity during anti-thymocyte globulin: That's CARPA! 36
Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: A retrospective analysis 35
PEG-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION : A SINGLE-CENTRE EXPERIENCE 34
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. 33
A pilot study of the recombinant soluble human tumor necrosis factor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. 33
New perspectives on the use of nucleic acids in pharmacological applications: inhibitory action of extracellular self-DNA in biological systems 33
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 32
CIRCULATING MEGAKARYOCYTE-DERIVED CELLS DETECTED BY FLOW CYTOMETRY AS MARKER OF AGGRESSIVE NEOPLASM OF MEGAKARYOCYTIC LINEAGE IN ACUTE MEGAKARYOBLASTIC LEUKEMIA AND ALLIED MALIGNANCIES PRESENTING AS PRIMARY MYELOFIBROSIS 32
Twenty years of the Italian Fanconi Anemia Registry: Where we stand and what remains to be learned 31
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study 31
Application of the molecular analsysis of the T –cell receptor repertoire in the study of immune-mediated hematologic disease. 30
Retroperitoneal extramedullary relapse after blinatumomab in acute lymphoblastic leukemia failing haplo-identical bone marrow transplantation. 30
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for proximal complement inhibition? A position paper from the SAAWP of the EBMT 30
Aplastic anemia: immunosuppressive therapy in 2010. 29
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High Dose Cyclophosphamide 29
Eculizumab treatment modifies the immune profile of PNH patients. 28
Aplastic anemia: immunosuppression. Current challenges and future goals in immunosuppression for aplastic anemia. 28
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anemia and single-lineage marrow failure: a pilot study and a survey from EBMT WPSAA. 28
THIOTEPA AND MELPHALAN AS NEW CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE LYELOMA 28
CHRONIC GRAFT Vs HOST DISEASE OF THE GENITAL TRACT: DIAGNOSIS, CLINICAL IMPACT AND MANAGEMENT FROM SURVEILLANCE PROGRAM IN A PRELIMINARY COHORT 28
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria 28
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 27
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 27
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 27
XM02 PLUS CHEMOTHERAPY IS SAFE AND EFFECTIVE IN STEM CELL MOBILIZATION FOR PATIENTS CANDIDATED TO AUTOLOGOUS STEM CELL TRANSPLANTATION 26
Epidemiology of Acquired Bone Marrow Failure 26
Role of the Urokinase Receptor (uPaR) in the cross-talk of hematopoietic Stem Cells with the bone marrow environment 25
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions 25
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies 25
Aplastic anemia: management of adult patients. 24
Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. 24
Factor H interfers with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule 24
Oral dysplastic complications after HSCT: Single case series of multidisciplinary evaluation of 80 patients 24
Transplant results in adults with Fanconi anaemia 23
Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010 Meeting Report. 23
Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein (PrPc). 23
Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties 23
Network references for rare diseases: state of the art for the paroxysmal nocturnal hemoglobinuria 23
Therapeutic complement modulation for hematological diseases: Where we stand and where we are going 23
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 22
Stem cell transplantation for congenital dyserythropoietic anemia. An analysis from the European society for blood and marrow transplantation 22
Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis 22
Long lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant 21
Advances in understanding the pathogenesis of acquired aplastic anaemia 21
Allogeneic stem cell transplantation for acquired pure red cell aplasia 21
Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group 20
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia 18
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation 18
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. 18
Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups. 18
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going 18
Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party 18
Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita 18
Safety and Efficacy of the TerminalC5 Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. 17
Rabbit ATG for aplastic anaemia treatment: a backward step? 17
Small-molecule factor D inhibitors targeting the alternative complement pathway 17
Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria 16
T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. 16
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. 16
The european hematology association roadmap for european hematology research: A consensus document. 16
Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria 16
Immune insights into AA 16
Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group 16
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria 16
From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging 15
Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. 15
Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia 15
Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria 15
Stem cell transplantation in severe congenital neutropenia: An analysis from the European Society for Blood and Marrow Transplantation 15
Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria 15
Paroxysmal Nocturnal Hemoglobinuria 15
Fanconi Anemia 15
Clinical Effects of Eculizumab in PNH: Extravascular Hemolysis After Eculizumab Treatment 15
Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment 14
Prospective study of rabbit antithymocyte globulin and ciclosporin for aplastic anemia from the EBMT Severe Aplastic Anemia Working Party. 14
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. 14
Use of eltrombopag in aplastic anemia in Europe 14
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 14
Dissecting complement blockade for clinic use 14
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes 14
Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 14
Paroxysmal nocturnal hemoglobinuria: significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population. 13
Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. 13
Totale 2.549
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.441
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.441
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201913 0 0 0 0 0 0 0 0 0 0 6 7
2019/2020437 259 2 11 3 8 0 1 4 1 32 66 50
2020/2021303 52 14 13 9 36 25 12 3 25 2 23 89
2021/2022816 2 1 2 1 3 26 7 42 96 42 151 443
2022/2023920 191 79 18 33 106 97 9 107 130 90 49 11
2023/2024482 14 109 109 26 41 57 16 61 23 20 6 0
Totale 3.397